NO20010284L - Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) - Google Patents

Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)

Info

Publication number: NO20010284L
Authority: NO; Norway
Prior art keywords: disease; pacap; adenylate cyclase; activating polypeptide; pituitary adenylate
Prior art date: 1998-07-20

Application number

NO20010284A

Other languages

English (en)

Norwegian (no)

Other versions

NO20010284D0 (no

Inventor

Zheng Xin Dong

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-20

Filing date

2001-01-17

Publication date

2001-03-19

2001-01-17 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2001-01-17 Publication of NO20010284D0 publication Critical patent/NO20010284D0/no

2001-03-19 Publication of NO20010284L publication Critical patent/NO20010284L/no

Links

UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 title abstract 4
102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 title abstract 3
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
201000006474 Brain Ischemia Diseases 0.000 abstract 1
208000014644 Brain disease Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010016654 Fibrosis Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000026072 Motor neurone disease Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 abstract 1
108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 abstract 1
208000001647 Renal Insufficiency Diseases 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
208000007107 Stomach Ulcer Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000004761 fibrosis Effects 0.000 abstract 1
201000005917 gastric ulcer Diseases 0.000 abstract 1
201000001881 impotence Diseases 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
208000005264 motor neuron disease Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000016273 neuron death Effects 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Toxicology (AREA)

NO20010284A 1998-07-20 2001-01-17 Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) NO20010284L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11954098A	1998-07-20	1998-07-20
PCT/EP1999/003020 WO2000005260A1 (en)	1998-07-20	1999-04-30	Peptide analogues of pacap

Publications (2)

Publication Number	Publication Date
NO20010284D0 NO20010284D0 (no)	2001-01-17
NO20010284L true NO20010284L (no)	2001-03-19

Family

ID=22384966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010284A NO20010284L (no)	1998-07-20	2001-01-17	Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)

Country Status (15)

Country	Link
EP (2)	EP1098906B1 (de)
JP (2)	JP2002521390A (de)
AR (1)	AR019131A1 (de)
AT (1)	ATE449789T1 (de)
AU (1)	AU3826899A (de)
CA (1)	CA2335341A1 (de)
CZ (1)	CZ2001253A3 (de)
DE (1)	DE69941708D1 (de)
DK (1)	DK1098906T3 (de)
ES (1)	ES2335827T3 (de)
HU (1)	HUP0104934A3 (de)
NO (1)	NO20010284L (de)
PL (1)	PL345583A1 (de)
TW (1)	TWI221845B (de)
WO (1)	WO2000005260A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6972319B1 (en)	1999-09-28	2005-12-06	Bayer Pharmaceuticals Corporation	Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
CA2379604A1 (en) *	1999-09-28	2001-04-05	Bayer Corporation	Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
EP1233811A2 (de)	1999-11-12	2002-08-28	Leo Rubin	Verfahren zur behandlung von herzstillstand oder pulmonarer hypertension und substanzen zur verwendung dafür mit vasoaktivem intestinalen polypeptid und kardiales gerät zur elektrischen und chemischen regulation sowie verwendungsverfahren dafür
US6489297B1 (en)	2000-02-18	2002-12-03	Dabur Research Foundation	Vasoactive intestinal peptide analogs
WO2001060863A1 (en) *	2000-02-18	2001-08-23	Dabur Research Foundation	Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
AU2072002A (en) *	2000-11-28	2002-06-11	Mondobiotech Sa	Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
JP2002293799A (ja) *	2001-03-29	2002-10-09	Itoham Foods Inc	新規ペプチド及びそれを含有する消化管運動抑制剤
AR036400A1 (es) *	2001-08-30	2004-09-08	Stem Cell Therapeutics Inc	Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) *	2001-09-14	2012-02-15	Stem Cell Therapeutics Inc	Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
AU2003228050A1 (en) *	2002-05-03	2003-11-17	Neuronova Ab	Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
AU2003236072B2 (en) *	2002-06-10	2008-10-23	Mondobiotech Ag	Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
CA2492442A1 (en)	2002-07-31	2004-02-05	Stem Cell Therapeutics Inc.	Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2004062684A2 (en)	2003-01-16	2004-07-29	D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven	Treatment of thrombocytopenia with inhibitors of pacap
CA2556266A1 (en)	2004-02-13	2005-08-25	Stem Cell Therapeutics Corp.	Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US7595294B2 (en) *	2004-10-08	2009-09-29	Transition Therapeutics, Inc.	Vasoactive intestinal polypeptide pharmaceuticals
JP2006306770A (ja) *	2005-04-27	2006-11-09	Nidek Co Ltd	眼疾患治療剤
WO2007036033A1 (en)	2005-09-27	2007-04-05	Stem Cell Therapeutics Corp.	Oligodendrocyte precursor cell proliferation regulated by prolactin
CN101296708B (zh)	2005-10-26	2011-12-07	伊莱利利公司	选择性vpac2受体肽激动剂
CA2779496A1 (en) *	2009-11-02	2011-05-05	The Administrators Of The Tulane Educational Fund	Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CA2901231C (en) *	2013-02-15	2020-06-23	Thomas Jefferson University	Kit comprising lyophilized compositions for tumor imaging
CA2906737C (en)	2013-03-15	2023-08-15	Amgen Inc.	Human pac1 antibodies
US20160122406A1 (en) *	2013-06-07	2016-05-05	The Administrators Of The Tulane Educational Fund	Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015023890A1 (en)	2013-08-14	2015-02-19	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
WO2015100353A1 (en)	2013-12-27	2015-07-02	Dignity Health	Diagnosing and treating alzheimer's disease
WO2016044224A1 (en)	2014-09-15	2016-03-24	Amgen Inc.	Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US10822408B2 (en)	2015-12-15	2020-11-03	Amgen Inc.	PACAP antibodies and uses thereof
US11021514B2 (en)	2016-06-01	2021-06-01	Athira Pharma, Inc.	Compounds
EP3565573B1 (de)	2017-01-05	2023-08-23	The Regents of The University of California	Pac1-rezeptor-agonisten (maxcaps) und verwendungen davon
SG11202006610YA (en)	2018-01-12	2020-08-28	Amgen Inc	Pac1 antibodies and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CS277405B6 (en) *	1986-06-12	1993-03-17	Vyzk Ustav Farm Biochem Sp	Peptides with 1-amino-1-cycloalkane carboxylic acid
US5128242A (en) *	1989-06-19	1992-07-07	The Administrators Of The Tulane Educational Fund	Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5623050A (en) *	1991-08-22	1997-04-22	Takeda Chemical Industries, Ltd.	Stable polypeptides having c-AMP production enhancing activity and the use thereof
JP3354173B2 (ja) *	1991-08-22	2002-12-09	武田薬品工業株式会社	ポリペプチドおよびその用途
JPH10505863A (ja) *	1994-09-22	1998-06-09	ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド	脳障害の予防および治療のための方法および医薬組成物
EP0820296A4 (de) *	1995-04-14	1999-06-30	Univ Tulane	Analoge von wachstumshormon-freisetzungsfaktor
US5753206A (en) *	1995-06-07	1998-05-19	Immunomedics, Inc.	Radiometal-binding analogues of luteinizing hormone releasing hormone
EP0796867B1 (de) *	1995-06-09	2003-11-05	Itoham Foods Inc.	Peptide, bronchodilator und den blutstrom verbesserndes mittel
US5723577A (en) *	1995-07-13	1998-03-03	Biomeasure Inc.	Analogs of parathyroid hormone
US5955574A (en) *	1995-07-13	1999-09-21	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.	Analogs of parathyroid hormone
AU6846196A (en) *	1995-08-15	1997-03-12	International Software Machines	Programmable compiler

1999
- 1999-04-30 PL PL99345583A patent/PL345583A1/xx not_active Application Discontinuation
- 1999-04-30 CA CA002335341A patent/CA2335341A1/en not_active Abandoned
- 1999-04-30 EP EP99920844A patent/EP1098906B1/de not_active Expired - Lifetime
- 1999-04-30 WO PCT/EP1999/003020 patent/WO2000005260A1/en not_active Ceased
- 1999-04-30 ES ES99920844T patent/ES2335827T3/es not_active Expired - Lifetime
- 1999-04-30 CZ CZ2001253A patent/CZ2001253A3/cs unknown
- 1999-04-30 DE DE69941708T patent/DE69941708D1/de not_active Expired - Lifetime
- 1999-04-30 JP JP2000561216A patent/JP2002521390A/ja not_active Ceased
- 1999-04-30 AU AU38268/99A patent/AU3826899A/en not_active Abandoned
- 1999-04-30 EP EP09174102A patent/EP2161282A1/de not_active Withdrawn
- 1999-04-30 DK DK99920844.0T patent/DK1098906T3/da active
- 1999-04-30 HU HU0104934A patent/HUP0104934A3/hu unknown
- 1999-04-30 AT AT99920844T patent/ATE449789T1/de not_active IP Right Cessation
- 1999-05-03 AR ARP990102060A patent/AR019131A1/es not_active Application Discontinuation
- 1999-05-29 TW TW088108929A patent/TWI221845B/zh not_active IP Right Cessation
2001
- 2001-01-17 NO NO20010284A patent/NO20010284L/no not_active Application Discontinuation
2010
- 2010-03-23 JP JP2010066707A patent/JP2010189398A/ja not_active Ceased

Also Published As

Publication number	Publication date
EP1098906B1 (de)	2009-11-25
EP2161282A1 (de)	2010-03-10
JP2002521390A (ja)	2002-07-16
NO20010284D0 (no)	2001-01-17
AU3826899A (en)	2000-02-14
HUP0104934A2 (hu)	2002-04-29
EP1098906A1 (de)	2001-05-16
HUP0104934A3 (en)	2002-05-28
AR019131A1 (es)	2001-12-26
JP2010189398A (ja)	2010-09-02
ES2335827T3 (es)	2010-04-05
CA2335341A1 (en)	2000-02-03
CZ2001253A3 (cs)	2001-11-14
WO2000005260A1 (en)	2000-02-03
TWI221845B (en)	2004-10-11
DK1098906T3 (da)	2010-03-29
DE69941708D1 (de)	2010-01-07
ATE449789T1 (de)	2009-12-15
PL345583A1 (en)	2001-12-17

Legal Events

Date	Code	Title	Description
2003-01-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20010284L (no)	2001-03-19	Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP)
Jensen et al.	1989	Interaction of CCK with pancreatic acinar cells
Hirose et al.	2003	N-acyl 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist
Cabrele et al.	2000	Molecular characterization of the ligand–receptor interaction of the neuropeptide Y family
Okamura et al.	2008	Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1, 1-diphenyl-tetrahydro-oxazolo [3, 4-a] pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor
US8729227B2 (en)	2014-05-20	Compounds for control of appetite
CA2162924A1 (en)	1994-11-24	New peptide antagonists at glutamate and nmda receptors
Kaga et al.	2001	Emerging functions of neuropeptide Y Y2 receptors in the brain
CZ287948B6 (cs)	2001-03-14	Peptidový derivát uvolňující růstový hormon, farmaceutický prostředek s jeho obsahem a jejich použití
Bock et al.	1994	Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility
JPS63258894A (ja)	1988-10-26	アミノ酸誘導体
EP1116727A4 (de)	2002-01-02	Peptid-derivat
Mashal et al.	1983	The effects of cholecystokinin on dopaminergic mechanisms in rat striatum
Green et al.	2004	Lys9 for Glu9 substitution in glucagon-like peptide-1 (7–36) amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1 (9–36) amide and exendin (9–39)
Blommaert et al.	1997	Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor
NO912772L (no)	1992-01-20	Pyrazolidinon cck, gastrinantagonister og farmasoeytiske formuleringer derav.
Seko et al.	2001	Structure–activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers
Gottschlich et al.	1994	EMD 61 753 as a favourable representative of structurally novel arylacetamido-type K opiate receptor agonists
US10981958B2 (en)	2021-04-20	Peptide modulator of purinergic receptors
Wei et al.	2004	Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives
WO2004083867A3 (en)	2005-03-17	Modulators of g protein-coupled formyl peptide receptor-like 2 and their therapeutic use against cell death-related disorders
EA014553B1 (ru)	2010-12-30	Фармацевтические композиции для лечения заболеваний, связанных с нейротрофинами
Lorinet et al.	1989	Pancreastatin inhibits insulin release from Rin m 5F cells: reversion by pertussis toxin
Martire et al.	1992	Neuropeptide Y interaction with the adrenergic transmission line: a study of its effect on alpha-2 adrenergic receptors
DeCarr et al.	2007	Identification of selective neuropeptide Y2 peptide agonists